Humacyte reported a transformative second quarter 2026, headlined by positive Phase 3 results for its dialysis pipeline and the initial commercial traction of Symvess. While the company continues to operate at a net loss, it has implemented significant cost-saving measures and secured additional capital to fund its path toward multiple regulatory milestones.
Key Highlights
- Phase 3 V012 trial results for female dialysis patients showed the ATEV outperformed AV fistula, providing an average of 91 more catheter-free days (p=0.0007).
- In May 2026, the company reduced its workforce by 45 employees, a restructuring move expected to generate $14.3 million in net savings during fiscal 2026.
- Humacyte strengthened its liquidity through a June 2026 public offering that raised $57.5 million in gross proceeds, ending the quarter with $80.3 million in cash.